Autopsy report · NCT01944839
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Cause of deathNo reason given
Life of this trial
- Ran for about 3 years 4 months before it stopped.
- 619 participants enrolled.
- Results were posted on the registry 1 year 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Ophthotech Corporation
- Sponsor type
- Industry
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030; ranibizumab; E10030 sham intravitreal injection
- Participants
- 619
- Sites
- 115
- Countries
- Austria, Belgium, Brazil, Canada, Czechia, Estonia, Italy, Latvia, Poland, Slovakia, Switzerland, United Kingdom and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.